MASS 908 Devices Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1555279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.7%
TTM net income YoY-487.1%
TTM EPS YoY-384.6%
Revenue 3-yr CAGR11.5%
Net income 3-yr CAGR—
Margins
Gross margin52.3%
Operating margin-42.7%
Net margin-36.9%
FCF margin4.0%
EBITDA margin-34.9%
Returns
ROE-17.0%
ROA-12.4%
ROIC (approx.)-27.8%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets24.9%
Debt / equity0.00x
Current ratio5.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.12x
Accruals ratio-13.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $56.20M | $47.75M | $50.23M | $46.85M | $42.21M |
| Cost of revenue | $27.77M | $23.25M | $24.91M | $20.83M | $18.97M |
| Gross profit | $28.42M | $24.50M | $25.32M | $26.02M | $23.23M |
| R&D expense | $15.57M | $14.99M | $21.90M | $17.53M | $13.07M |
| SG&A expense | $38.53M | $39.46M | $46.07M | $43.88M | $32.23M |
| Operating income | -$39.42M | -$57.39M | -$42.76M | -$35.38M | -$22.07M |
| Interest expense | — | — | $201,000 | $129,000 | $486,000 |
| Pretax income | -$33.34M | -$53.14M | -$36.61M | -$33.56M | — |
| Income tax | -$66,000 | -$282,000 | -$211,000 | $0 | — |
| Net income | $19.49M | -$72.21M | -$36.40M | -$33.56M | -$22.17M |
| EBITDA | -$34.96M | -$52.71M | -$40.37M | -$33.77M | -$21.14M |
| EPS (basic) | 0.54 | -2.12 | -1.13 | -1.07 | -0.79 |
| EPS (diluted) | 0.54 | -2.12 | -1.13 | -1.07 | -0.79 |
| Weighted avg. shares (diluted) | 35.90M | 34.08M | 32.24M | 31.49M | 27.96M |
| Balance sheet | |||||
| Cash & equivalents | $70.52M | $44.20M | $121.21M | $188.59M | $224.13M |
| Short-term investments | $42.45M | $25.57M | $24.64M | $0 | — |
| Receivables | $11.33M | $8.85M | $8.99M | $10.03M | $16.38M |
| Inventory | $12.99M | $10.89M | $14.94M | $12.51M | $7.92M |
| Current assets | $144.56M | $103.06M | $173.79M | $215.63M | $252.89M |
| PP&E, net | $4.23M | $1.59M | $3.34M | $3.08M | $1.60M |
| Goodwill | $0 | $0 | $10.37M | $10.05M | — |
| Intangibles | $36.41M | $38.68M | $7.86M | $8.49M | — |
| Total assets | $190.07M | $159.48M | $202.98M | $242.59M | $260.91M |
| Current liabilities | $34.06M | $25.15M | $22.55M | $19.23M | $14.84M |
| Long-term debt | — | — | — | $15.00M | $15.00M |
| Total debt | — | — | — | $15.00M | $15.00M |
| Total liabilities | $46.37M | $44.88M | $37.49M | $51.99M | $46.30M |
| Shareholders' equity | $143.70M | $114.59M | $165.49M | $190.60M | $214.60M |
| Net debt | — | — | — | -$173.59M | -$209.13M |
| Shares outstanding | 36.32M | 35.10M | 32.52M | 31.86M | 31.08M |
| Cash flow statement | |||||
| Operating cash flow | -$23.69M | -$30.25M | -$25.06M | -$20.93M | -$29.08M |
| Capital expenditure | $955,000 | $602,000 | $2.04M | $2.04M | $737,000 |
| Free cash flow | -$24.64M | -$30.85M | -$27.10M | -$22.98M | -$29.82M |
| Investing cash flow | $50.75M | -$46.32M | -$26.40M | -$15.81M | -$737,000 |
| Financing cash flow | -$697,000 | -$376,000 | -$15.94M | $1.18M | $94.72M |
| Depreciation & amortization | $4.46M | $4.68M | $2.38M | $1.61M | $925,000 |
| Stock-based compensation | $9.85M | $11.76M | $9.79M | $7.21M | $2.50M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.